TG Therapeutics, Inc.

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:29:52 31/05/2024 am IST			5-day change	1st Jan Change
16.88 ^USD	+3.18%		-0.59%	-1.17%

01/05	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
01/05	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

TG Therapeutics, Inc. Announces Demise of Board Member, Mark Schoenebaum, MD

August 26, 2019 at 09:30 pm IST

TG Therapeutics, Inc. announced the passing of longtime Board Member, Mark Schoenebaum, MD.

Latest news about TG Therapeutics, Inc.

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05	MT
Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	01/05
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	01/05	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
North American Morning Briefing : Investors Brace -2-	29/04	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Sector Update: Health Care	19/04	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04	CI
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	14/03	MT
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01/03	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	29/02	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	29/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	26/02	MT
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	12/02	CI
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	05/02	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	11/01	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	11/01	MT
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	10/01	MT

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - Consortium of Multiple Sclerosis Centers Meeting - Abstract No:#9800

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for TG Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.89 USD

Average target price

31.5 USD

Spread / Average Target

+86.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TG THERAPEUTICS, INC.	-1.17%	2.42B
MODERNA, INC.	+52.36%	58.06B
IQVIA HOLDINGS INC.	-3.86%	40.53B
LONZA GROUP AG	+36.78%	38.99B
CELLTRION, INC.	-12.01%	26.56B
ICON PUBLIC LIMITED COMPANY	+14.13%	26.7B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.98B
BIO-TECHNE CORPORATION	+0.21%	12.17B
MEDPACE HOLDINGS, INC.	+25.96%	11.92B
UNITED THERAPEUTICS CORPORATION	+23.02%	12B

Other Biotechnology & Medical Research